Group 1 - The core point of the article is that Haier Biomedical has reported a total of 14,022 shareholders as of January 20, 2026 [1]

证券日报网讯1月22日，海尔生物在互动平台回答投资者提问时表示，公司致力于将管理层利益与公司 发展、股东价值深度绑定，已建立起与市场发展相适应、与公司经营业绩和个人业绩相匹配、与持续发 展相协调的管理层薪酬制度体系。此外，公司高度重视对投资者回报，自上市以来，公司已连续6年实 施分红，累计分红7.88亿元人民币，其中2024年度分红方案的分红比例进一步提升为40.31%；公司实控 人的一致行动人已三次增持公司股票，累计增持金额约3.84亿元；公司自身共推出了三轮股份回购计 划，累计回购金额共计约2.5亿元，并于2026年1月6日注销部分已回购股份145.96万股。公司向来注重规 范运作，勤勉履行信息披露义务，当前没有应披未披的信息。 ...

Core Viewpoint - Haier Biomedical has achieved significant growth in its overseas market, with over 35% of its total revenue coming from international sales, and a year-on-year growth of 20% expected in the first three quarters of 2025 [2] Group 1: Overseas Market Performance - The company has reported high double-digit growth in the European region, contributing to its overall overseas revenue increase [2] - The growth in overseas business is attributed to the company's localized operational system and the continuous expansion of its product categories [2] Group 2: Localization Strategy - Haier Biomedical has established localized operations in 18 countries and set up subsidiaries in the UK, Netherlands, and other locations [2] - The company focuses on understanding local user needs and employs localized planning, marketing, warehousing, and services to address core user pain points [2] Group 3: Brand Development - The company aims to become a globally trusted brand in life sciences, with a significant increase in overseas revenue, achieving a compound annual growth rate of over 20% from 2016 to 2024 [2] - Haier Biomedical's business now covers over 150 countries and regions worldwide, showcasing its extensive market reach [2]

海尔生物（688139.SH）1月22日在投资者互动平台表示，作为海尔集团旗下聚焦生命科学的科创板上 市公司，海尔生物以"全球用户信赖的生命科学世界级品牌"为目标，已将业务覆盖至全球150多个国家 和地区，实现了18个国家的本地化部署，海外市场收入占比已超过35%。基于全球范围的内生与外延发 展战略，公司将持续关注生命科学产业的优质标的，补强现有产业，扩大业务边界，布局高潜力赛道， 并将严格按照法律法规及时履行信息披露义务。 每经AI快讯，有投资者在投资者互动平台提问：当年海尔智家收购海外电器资产整合非常成功，海尔 生物是否会在医疗器械行业重演，对海外医疗资产有无收购目标标的？ （文章来源：每日经济新闻） ...

Core Viewpoint - Haier Biomedical's subsidiary, Haier Blood Technology Chongqing Co., Ltd., has received the first EU MDR certification for its plasma separation equipment, marking a significant milestone for the company in expanding its market presence in Europe and globally [2][5]. Group 1: Certification and Compliance - The MDR compliance assessment is a prerequisite for medical devices entering the EU market, ensuring product safety, performance, and post-market surveillance [5]. - The successful certification of Haier's plasma separation equipment demonstrates the company's adherence to EU regulations in product design, manufacturing, and quality control [5]. Group 2: Company Statements and Future Plans - Haier Biomedical's General Manager, Liu Zhanjie, emphasized that obtaining the MDR certificate is a recognition of the company's quality management system and positions Haier Blood Technology to compete globally [7]. - The company aims to leverage this certification as a new starting point to promote Chinese manufacturing solutions in global healthcare [7]. Group 3: TÜV Rheinland's Role - TÜV Rheinland serves as a notified body for EU medical device regulations, providing compliance assessments and certifications that enhance the competitiveness of "Made in China" products in international markets [8]. Group 4: Company Overview - Haier Blood Technology Chongqing Co., Ltd. was established in 2001 and specializes in comprehensive solutions for blood and blood component collection, processing, testing, storage, transportation, and usage [8]. - The company's main products include plasma separation machines, disposable centrifuge plasma separators, and various types of blood bags and related medical devices [8].

Core Viewpoint - The article presents the "Top 10 CO2 Incubator Products of 2025" based on user interest and browsing statistics, highlighting the growing attention towards domestic brands in the CO2 incubator market [2][4]. Summary by Sections Top 10 CO2 Incubator Products - The ranking includes products from both domestic and international brands, with the top three being: 1. Suzhou Beiyin's BIO-150RHP 2. WIGGENS' WCI-180 3. Haier Biomedical's HCP-168 [2][4]. Domestic vs. International Brands - Six out of the ten products are from domestic brands, indicating a significant user preference for local options. Suzhou Beiyin's product leads the list, while Haier Biomedical has two models in the top rankings [4]. - International brands such as WIGGENS, Thermo Scientific, and Esco maintain a strong presence, particularly in the high-end market, showcasing their technological advantages and brand reputation [4]. User Interest and Market Trends - The increased attention towards domestic CO2 incubators is attributed to policy incentives like "large-scale equipment updates" and changes in the international trade environment, which accelerate the domestic replacement process [4]. - The improvement in domestic brands' technological capabilities, manufacturing quality, and product reliability is also noted as a factor in gaining user trust and market recognition [4]. Product Features Overview - The article provides a brief introduction to each of the top products, highlighting key features such as: - Suzhou Beiyin's BIO-150RHP includes GMP-compliant data management and advanced temperature control systems [5][7]. - WIGGENS' WCI-180 features a direct heating system and dual-beam CO2 sensors for accurate monitoring [9][11]. - Haier Biomedical's HCP-168 utilizes fuzzy PID control for precise temperature management and includes a high-efficiency microbial filter [12][14]. Conclusion - The "Top 10 CO2 Incubator Products of 2025" reflects the evolving landscape of the CO2 incubator market, with a notable shift towards domestic brands gaining traction among users due to improved technology and favorable market conditions [4][36].

Core Viewpoint - Haier Biomedical focuses on providing AI-driven automated solutions for life sciences users, including pharmaceutical companies, research institutions, hospitals, and public health organizations, with products applied in over 150 countries and regions [1] Group 1 - The company targets pharmaceutical and life sciences sectors, as well as healthcare users such as hospitals and disease control centers [1] - Haier Biomedical integrates "AI + automation" into its products and solutions, enhancing their capabilities [1] - The solutions cover various fields, including low-temperature storage, laboratory applications, hospital medication, and blood technology [1]

Group 1 - The core point of the article is that Haier Biomedical has reported the total number of its shareholders as of January 10, 2026, which stands at 13,313 households [2]

证券代码：688139 证券简称：海尔生物 公告编号：2026-004 青岛海尔生物医疗股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/14 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 日~2026 年 月 13 | 1 | 月 | 14 | 1 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购价格上限 | 49.5367元/股 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 3,087,899股 | | | | | | 实际回购股数占总股本比例 | 0.9757% | | | | | | 实际回购金 ...

Group 1 - The company Haier Biomedical (688139.SH) completed a share buyback on January 13, 2026, repurchasing a total of 3,087,899 shares, which represents 0.9757% of the company's total share capital [1] - The highest price for the repurchased shares was 34.69 CNY per share, while the lowest price was 29.86 CNY per share, with an average repurchase price of 32.39 CNY per share [1] - The total amount spent on the share buyback reached 100.0042 million CNY (excluding transaction fees), achieving the lower limit of the total funds allocated for the buyback plan without exceeding the upper limit [1]